REVB

Revelation Biosciences, Inc., a clinical -stage biopharmaceutical company, focuses on the development or commercialization of innate immune system therapeutics and diagnostics. The company's lead therapeutic candidate is REVTx-99, an anti -viral nasal drop for the prevention or treatment of respiratory viral infections, as well as for the prevention or treatment of nasal congestion due to allergies or chronic rhinosinusitis. Its lead diagnostic is the REVDx -501, a rapid test kit to detect various respiratory viral infections. The company also develops REVTx-200, an intranasal immunomodulator adjunct to be used in combination with an intramuscular vaccination. Revelation Biosciences, Inc. was founded in 2019 and is headquartered in San Diego, California.